) --The 2012 BIO CEO & Investor Conference kicks off this morning here at the Waldorf-Astoria Hotel.

The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks.

Biotech companies scheduled to present today include

Celsion Pharmaceuticals

(CLSN) - Get Report


Cyclacel Pharmaceuticals

(CYCC) - Get Report


Chelsea Therapeutics



Navidea Biopharmaceuticals

(NAVB) - Get Report


Galena Biopharma



Titan Pharmaceuticals

(TTNP) - Get Report





Today's agenda also includes panel discussions on cancer clinical trials, the "beta amyloid debate" in Alzheimer's disease drug research and biotech financing.

On Tuesday, biotech and drug presenters include

Delcath Systems



Keryx Pharmaceuticals

(KERX) - Get Report





Acorda Therapeutics

(ACOR) - Get Report


Idenix Pharmaceuticals



Gilead Sciences'

(GILD) - Get Report

President John Milligan will also be featured in a "fireside chat."

To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag.

--Written by Adam Feuerstein in New York.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:






and become a fan on


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.